Literature DB >> 30176675

The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis.

Anna C Garza-Mayers1,2, Radhika Shah1, David B Sykes3,2, Sagar U Nigwekar4,2, Daniela Kroshinsky1,2.   

Abstract

Calciphylaxis is a disease of dermal arteriolar calcification that results in necrosis. It commonly occurs in individuals with end-stage renal disease (ESRD) on hemodialysis and is associated with a high morbidity and mortality. Warfarin use is an identified risk factor. Twenty patients with ESRD on dialysis with calciphylaxis who were treated with apixaban for indications of deep vein thrombosis or atrial fibrillation were identified. There were no reports of thrombosis. Three individuals experienced bleeding requiring a transfusion, and anticoagulation was resumed without further event. Findings suggest that apixaban may be a safe and effective alternative to warfarin in patients with ESRD on dialysis with calciphylaxis.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Apixaban; Calcific uremic arteriolopathy; Calciphylaxis; Dialysis; Warfarin

Year:  2018        PMID: 30176675     DOI: 10.1159/000491881

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

Review 1.  Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:  Nathan P Clark
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Role of direct oral anticoagulants in patients with kidney disease.

Authors:  Vimal K Derebail; Michelle N Rheault; Bryce A Kerlin
Journal:  Kidney Int       Date:  2019-12-24       Impact factor: 10.612

3.  Perioperative Management of Calciphylaxis: Literature Review and Treatment Recommendations.

Authors:  Natalie Strand; Jillian Maloney; Samuel Wu; Molly Kraus; Rick Schneider; Diego Gomez; Steven Char
Journal:  Orthop Rev (Pavia)       Date:  2022-08-25

Review 4.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

Review 5.  Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.

Authors:  Harpreet S Bhatia; Jonathan C Hsu; Robert J Kim
Journal:  Clin Cardiol       Date:  2018-10-25       Impact factor: 2.882

6.  Correlation between clinical and pathological features of cutaneous calciphylaxis.

Authors:  Puja Dutta; Kristine M Chaudet; Rosalynn M Nazarian; Daniela Kroshinsky; Sagar U Nigwekar
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

7.  Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study.

Authors:  Raphaël Gaisne; Morgane Péré; Victorio Menoyo; Maryvonne Hourmant; David Larmet-Burgeot
Journal:  BMC Nephrol       Date:  2020-02-26       Impact factor: 2.388

8.  Non-Uremic Calciphylaxis: An Unexpected Complication With Recombinant Human Parathyroid Hormone.

Authors:  Cory DeClue; Bhavana Chinnakotla; Michael J Gardner
Journal:  Cureus       Date:  2021-05-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.